Abstracts for the American Society of Clinical Oncology are out, with new data from Pfizer’s ADC, Nimbus Therapeutics’ immuno-oncology drug, Nuvation Bio’s ROS1 inhibitor and new data from J&J in prostate cancer.
- After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug: The company released updated data for NDI-101150, the biotech’s sole clinical-stage drug being tested in cancer patients with advanced solid tumors (LINK)
- Merck, Kelun trumpet ADC’s Phase 3 breast cancer data: The anti-TROP2 reduced patients’ risk of disease progression or death by 69% compared to chemotherapy (LINK)
- Nuvation Bio shares pivotal China data for cancer drug from AnHeart buyout: The US-China biotech showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol Myers Squibb a run for their money (LINK)
- Pfizer’s ADC data that convinced it to start a Phase 3 lung cancer trial: The drugmaker released updated data for the drug it acquired through its $43 billion deal with Seagen that closed last year (LINK)
- J&J plans for capped, flexible dosing after four patient deaths in early study of actinium prostate cancer drug: An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 led to three patients seeing their tumors shrink substantially, but four patient deaths overall (LINK)
ASCO will officially begin on May 31, with late-breaking data being presented over the weekend. To sign up for Endpoints News‘ virtual recap and an interview with National Cancer Institute Director Kimryn Rathmell, click here.